Janssen’s psoriasis drug shows promise for childhood diabetes
Type 1 diabetes accounts for approximately 10% of diabetes cases in the UK
Read Moreby Jen Brogan | Aug 7, 2024 | News | 0
Type 1 diabetes accounts for approximately 10% of diabetes cases in the UK
Read Moreby John Pinching | Sep 1, 2023 | News | 0
The AI platform and expertise will be combined to discover novel targets for haematological cancers
Read Moreby John Pinching | Jul 24, 2023 | News | 0
The treatment is a monotherapy for treating adult patients with refractory or relapsed multiple myeloma
Read Moreby John Pinching | Jul 10, 2023 | News | 0
Period to remission was shortened with esketamine nasal spray in both sub-groups within study
Read Moreby John Pinching | Jun 9, 2023 | News | 0
Erdafitinib boosted survival in patients with certain conditions including metastatic urothelial carcinoma
Read Moreby John Pinching | Apr 26, 2023 | News | 0
Recommendation concerns routine use across the NHS as therapy for multiple myeloma
Read Moreby John Pinching | Apr 24, 2023 | News | 0
Treatment involves the treatment of adults with metastatic castration-resistant prostate cancer
Read Moreby John Pinching | Mar 31, 2023 | News | 0
Results from trial showed a long-term response among specific lung cancer population
Read Moreby John Pinching | Feb 27, 2023 | News | 0
If approved company’s prostate cancer therapy will be the first dual-action tablet available in EU
Read Moreby John Pinching | Feb 20, 2023 | News | 0
Research concerns the effect of niraparib when combined with abiraterone acetate plus prednisone
Read Moreby John Pinching | Jan 4, 2023 | News | 0
European Medicines Agency will consider therapy for the treatment of patients with multiple myeloma
Read Moreby Emily Kimber | Aug 25, 2022 | News | 0
Teclistamab is the first bispecific antibody worldwide to be approved for patients with relapsed and refractory multiple myeloma
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
